Document Type : Original Paper


1 1 Department of Genetics, Faculty of Basic Sciences, Islamic Azad University, North Tehran Branch, Tehran, Islamic Republic of Iran

2 2 Department of Genetics, Faculty of Basic Sciences, Islamic Azad University, North Tehran Branch, Tehran, Islamic Republic of Iran

3 3 Department of Genetics, Faculty of Basic Sciences, Islamic Azad University, Saveh Branch, Saveh, Islamic Republic of Iran


Alzheimer's disease is the most common cause of dementia in the elderly. One of the polymorphisms in Alzheimer's disease is rs7920721 in the ECHDC3 gene, which has not been studied in the population of Iranian Alzheimer's patients and was evaluated in the present study. In 2021, 100 patients with Alzheimer's disease and 100 healthy controls performed the current case-control analysis. Following blood sampling and DNA extraction, rs7920721 polymorphism was examined using Tetra ARMS PCR. The frequency of AA, AG and GG genotypes in rs7920721 in the control group was 89, 10, and 1%, respectively; in people with Alzheimer's disease, they were 73, 23, and 4%, respectively (P = 0.014). The frequency of A and G alleles in the control group was 94% and 6%, respectively, and in people with Alzheimer's disease, they were 84.5% and 15.5%, respectively (P = 0.046). The value (OR = 2.874) (CI 95% = 1.43-5.77) indicated an increased probability of disease in the presence of polymorphism. Both the case and control populations were also in the Hardy-Weinberg equilibrium. The results of the present study showed that the presence of the G allele in rs7920721 of the ECHDC3 gene could be associated with an increased risk of Alzheimer's disease in the Iranian population. As a result, this polymorphism can be introduced as a potential biomarker for Alzheimer's disease.


Main Subjects

  1. Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000 Research. 2018;7.
  2. Association As. 2018 Alzheimer's disease facts and figures. Alzheimers. Dement. 2018;14(3):367-429.
  3. Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer’s disease. Nat. Neurosci. 2020;23(3):311-22.
  4. Liu Y, Zhong X, Shen J, Jiao L, Tong J, Zhao W, et al. Elevated serum TC and LDL-C levels in Alzheimer’s disease and mild cognitive impairment: A meta-analysis study. Brain Res. 2020;1727:146554.
  5. Xu W, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer's disease. JNNP. 2015;86(12):1299-306.
  6. Matsuzaki T, Sasaki K, Hata J, Hirakawa Y, Fujimi K, Ninomiya T, et al. Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study. Neurology. 2011;77(11):1068-75.
  7. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-81.
  8. Versmissen J, Oosterveer DM, Blommesteijn-Touw AC, van Vark-van der Zee L, Vongpromek R, Mulder M, et al. Response to the Letter by Singh et al Regarding “Apolipoprotein Isoform E4 Does Not Increase Coronary Heart Disease Risk in Carriers of Low-Density Lipoprotein Receptor Mutations”. Circ. Cardiovasc. Genet. 2012;5(2):e14-e.
  9. Nägga K, Gustavsson A-M, Stomrud E, Lindqvist D, van Westen D, Blennow K, et al. Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later. Neurology. 2018;90(1):e73-e81.
  10. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimer's Dis. 2006;9(s3):151-3.
  11. Agnihotri G, Liu H-w. Enoyl-CoA hydratase: reaction, mechanism, and inhibition. Bioorg. Med. Chem. 2003;11(1):9-20.
  12. Duarte MKRN, de Araújo JNG, Duarte VHR, de Oliveira KM, de Oliveira JM, Carioca AAF, et al. The relationship of the oleic acid level and ECHDC3 mRNA expression with the extent of coronary lesion. Lipids Health Dis. 2016;15(1):1-6.
  13. Yin J, Feng W, Yuan H, Yuan J, Wu Y, Liu X, et al. Association analysis of polymorphisms in STARD6 and near ECHDC3 in Alzheimer’s disease patients carrying the APOE ε4 Allele. Neuropsychiatr. Dis. Treat. 2019;15:213.
  14. Kim YJ, Paik J-W, Kang WS, Kim SK, Lee KJ, Na HR, et al. Genetic association of STARD6 polymorphisms with Alzheimer's disease in a Korean population. J. Neurol. Sci. 2016;366:100-1.
  15. Eicher JD, Wakabayashi Y, Vitseva O, Esa N, Yang Y, Zhu J, et al. Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction. Platelets. 2016;27(3):230-9.
  16. Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM, et al. Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation. 2015;131(23):2061-9.


  1. Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, et al. Transethnic genome‐wide scan identifies novel Alzheimer's disease loci. Alzheimers. Dement. 2017;13(7):727-38.
  2. Lambert J-C, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013;45(12):1452-8.
  3. Liu JZ, Erlich Y, Pickrell JK. Case–control association mapping by proxy using family history of disease. Nat. Genet. 2017;49(3):325-31.
  4. Torres M, Price SL, Fiol-deRoque MA, Marcilla-Etxenike A, Ahyayauch H, Barceló-Coblijn G, et al. Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer's disease. Biochim Biophys Acta Biomembr BBA-BIOMEMBRANES. 2014;1838(6):1680-92.
  5. Mohaibes RJ, Fiol-deRoque MA, Torres M, Ordinas M, López DJ, Castro JA, et al. The hydroxylated form of docosahexaenoic acid (DHA-H) modifies the brain lipid composition in a model of Alzheimer's disease, improving behavioral motor function and survival. Biochim Biophys Acta Biomembr BBA-BIOMEMBRANES. 2017;1859(9):1596-603.
  6. Sarrafpour S, Ormseth C, Chiang A, Arakaki X, Harrington M, Fonteh A. Lipid metabolism in late-onset Alzheimer’s disease differs from patients presenting with other dementia phenotypes. IJERPH. 2019;16(11):1995.
  7. Chew H, Solomon VA, Fonteh AN. Involvement of lipids in Alzheimer’s disease pathology and potential therapies. Front. Physiol. 2020;11:598.
  8. Tábuas-Pereira M, Santana I, Guerreiro R, Brás J. Alzheimer’s disease genetics: Review of Novel Loci associated with disease. Curr. Genet. Med. Rep. 2020;8(1):1-16.
  9. Yu M, Nho K, Risacher SL, Chumin EJ, West JD, Tharp M, et al., editors. Transcriptomic profiles underlying functional brain networks at different stages of Alzheimer’s disease. 2020 AAIC.; 2020: ALZ.
  10. Tan M-S, Yang Y-X, Xu W, Wang H-F, Tan L, Zuo C-T, et al. Associations of Alzheimer’s disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. Alzheimer's res. & ther. 2021;13(1):1-11.